Cargando…
Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527374/ https://www.ncbi.nlm.nih.gov/pubmed/36190677 http://dx.doi.org/10.1007/s43440-022-00419-3 |
| _version_ | 1784801071973007360 |
|---|---|
| author | Flisiak, Robert Zarębska-Michaluk, Dorota Rogalska, Magdalena Kryńska, Justyna Anna Kowalska, Justyna Dutkiewicz, Ewa Dobrowolska, Krystyna Jaroszewicz, Jerzy Moniuszko-Malinowska, Anna Rorat, Marta Podlasin, Regina Tronina, Olga Rzymski, Piotr |
| author_facet | Flisiak, Robert Zarębska-Michaluk, Dorota Rogalska, Magdalena Kryńska, Justyna Anna Kowalska, Justyna Dutkiewicz, Ewa Dobrowolska, Krystyna Jaroszewicz, Jerzy Moniuszko-Malinowska, Anna Rorat, Marta Podlasin, Regina Tronina, Olga Rzymski, Piotr |
| author_sort | Flisiak, Robert |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9527374 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95273742022-10-03 Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance Flisiak, Robert Zarębska-Michaluk, Dorota Rogalska, Magdalena Kryńska, Justyna Anna Kowalska, Justyna Dutkiewicz, Ewa Dobrowolska, Krystyna Jaroszewicz, Jerzy Moniuszko-Malinowska, Anna Rorat, Marta Podlasin, Regina Tronina, Olga Rzymski, Piotr Pharmacol Rep Correction Springer International Publishing 2022-10-03 2022 /pmc/articles/PMC9527374/ /pubmed/36190677 http://dx.doi.org/10.1007/s43440-022-00419-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Flisiak, Robert Zarębska-Michaluk, Dorota Rogalska, Magdalena Kryńska, Justyna Anna Kowalska, Justyna Dutkiewicz, Ewa Dobrowolska, Krystyna Jaroszewicz, Jerzy Moniuszko-Malinowska, Anna Rorat, Marta Podlasin, Regina Tronina, Olga Rzymski, Piotr Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance |
| title | Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance |
| title_full | Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance |
| title_fullStr | Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance |
| title_full_unstemmed | Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance |
| title_short | Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance |
| title_sort | correction: real-world experience with molnupiravir during the period of sars-cov-2 omicron variant dominance |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527374/ https://www.ncbi.nlm.nih.gov/pubmed/36190677 http://dx.doi.org/10.1007/s43440-022-00419-3 |
| work_keys_str_mv | AT flisiakrobert correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance AT zarebskamichalukdorota correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance AT rogalskamagdalena correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance AT krynskajustynaanna correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance AT kowalskajustyna correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance AT dutkiewiczewa correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance AT dobrowolskakrystyna correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance AT jaroszewiczjerzy correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance AT moniuszkomalinowskaanna correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance AT roratmarta correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance AT podlasinregina correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance AT troninaolga correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance AT rzymskipiotr correctionrealworldexperiencewithmolnupiravirduringtheperiodofsarscov2omicronvariantdominance |